Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Multiplex Analysis of Adipose-Derived Stem Cell (ASC) Immunophenotype Adaption to In Vitro Expansion.

Peng Q., Duda M., Ren G., Xuan Z., Pennisi CP., Porsborg SR.

Laboratory Study on Face & Skin, published in Cells (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cells (2021)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
33499095
PMCID
PMC7911224
DOI
10.3390/cells10020218
Citations
10

Abstract (original English)

In order to enhance the therapeutic potential, it is important that sufficient knowledge regarding the dynamic changes of adipose-derived stem cell (ASC) immunophenotypical and biological properties during in vitro growth is available. Consequently, we embarked on a study to follow the evolution of highly defined cell subsets from three unrelated donors in the course of eight passages on tissue culture polystyrene. The co-expression patterns were defined by panels encompassing seven and five cell surface markers, including CD34, CD146, CD166, CD200, CD248, CD271, and CD274 and CD29, CD31, CD36, CD201, and Stro-1, respectively. The analysis was performed using multichromatic flow cytometry. We observed a major paradigm shift, where the CD166-CD34 + combination which was found across all cell subsets early in the culture was replaced by the CD166 + phenotype as the population homogeneity increased with time. At all analysis points, the cultures were dominated by a few major clones that were highly prevalent in most of the donors. The selection process resulted in two predominant clones in the larger panel (CD166 + CD34 - CD146 - CD271 - CD274 - CD248 - CD200 - and CD166 + CD34 + CD146 - CD271 - CD274 - CD248 - CD200 - ) and one clone in the smaller panel (CD29 + CD201 + CD36 - Stro-1 - CD31 - ). The minor subsets, including CD166 + CD34 - CD146 - CD271 + CD274 - CD248 - CD200 - a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueBiomarkersCell ProliferationCells, CulturedHumansImmunophenotypingStem CellsTissue Donors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research